Compare Amylx Pharmaceuticals Inc (AMLX) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Invesco S&P 500 High Div Low Volatility ETF trades at $51.9. Which is the better fit depends on your goals.
| AMLX | SPHD | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | — |
52-Week High | $18.70 | $52.63 |
52-Week Low | $7.64 | $46.96 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
SPHD trades at $51.82, up 0.76% with a bullish technical outlook supported by moving averages and strong trend momentum indicators. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering a 4.5% SEC yield with monthly distributions. Recent news highlights its defensive positioning and reliability for income investors, though historical returns have lagged the broader market.
SPHD presents a conservative income opportunity with defensive sector exposure, but faces underperformance risk versus growth-oriented ETFs. The bullish technical setup and consistent dividend payments support near-term stability, though long-term total return potential may be limited compared to the S&P 500.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
